The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday. In afternoon trade, the benchmark index is up 0.8% to 7,823.6 points.
Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:
Clinuvel Pharmaceuticals Limited (ASX: CUV)
The Clinuvel Pharmaceuticals share price is down 6.5% to $14.50. This appears to have been driven by a broker note out of Morgans this morning. According to the note, the broker has downgraded the biopharmaceutical company’s shares to a hold rating with a $16.00 price target. Morgans made the move partly on valuation grounds. It also highlights that there are risks around competition that investors should be considering.
Mesoblast Ltd (ASX: MSB)
The Mesoblast share price is down 4.5% to $1.07. This is despite the release of a positive announcement this morning from the biotechnology company. Mesoblast revealed that it has now resubmitted its biologic license application (BLA) for the approval of Ryoncil in the treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). Management expects an answer from the United States Food & Drug Administration (FDA) in two to six months. But with its shares up almost 300% over the past six months, it seems that some investors aren’t sticking around to find out if it will finally be approved.
Red Hill Minerals Ltd (ASX: RHI)
The Red Hill Minerals share price is down 21% to $6.19. This has been driven by the iron ore, gold, and base metals explorer’s shares going ex-dividend this morning for a big payout. Last week, the company announced a $1.50 per share fully franked dividend. This was in response to the receipt of $200 million milestone payment from Mineral Resources Ltd (ASX: MIN) relating to the Onslow Iron Project. Eligible shareholders can now look forward to receiving this dividend next week on 19 July. Based on yesterday’s close price, this payout represents a sizeable 19.2% dividend yield.
Resimac Group Ltd (ASX: RMC)
The Resimac share price is down 4% to 83 cents. Investors have been selling this non-bank lender’s shares today after it announced the sudden exit of its CEO. According to the release, Scott McWilliam has resigned from his employment with Resimac after 21 years of service. This includes six years as its CEO and three years as its joint CEO following the merger with Homeloans Limited. Mr McWilliam will take a period of leave before his employment contract ends on 1 September 2024.
The post Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clinuvel Pharmaceuticals right now?
Before you buy Clinuvel Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clinuvel Pharmaceuticals wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 24 June 2024
More reading
- Why is this ASX mining stock crashing 27% today?
- What’s going on with the Mesoblast share price today?
- Why Bowen Coking Coal, Clinuvel, Meteoric Resources, and Pilbara Minerals shares are falling
- Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher
- Why is this ASX 300 healthcare stock surging 12% today?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply